Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRSP with free AI briefings, catalyst countdowns, and dilution alerts.

CRSP · CRISPR Therapeutics AG

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.3B Cash on Hand
78.9mo Cash Runway
Follow CRSP by email Get an email when CRSP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRSP, unsubscribe in one click. Privacy

📣 What CRSP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Exagamglogene Autotemcel (CTX001) Beta-Thalassemia Phase 3 · NCT05356195 Active not recruiting
Evoncabtagene Pazurgedleucel (CTX110) B-cell Malignancy Phase 1/2 · NCT04035434 Terminated
Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR… B-cell Lymphoma Phase 1/2 · NCT05643742 Recruiting
CTX340 Hypertension Phase 1/2 · NCT07758634 Recruiting
CTX460 Alpha-1 Antitrypsin Deficiency (AATD) Phase 1/2 · NCT07850076 Recruiting
Motacabtagene Lurevgedleucel (CTX120) Multiple Myeloma Phase 1 · NCT04244656 Terminated
Volamcabtagene Durzigedleucel (CTX130) T Cell Lymphoma Phase 1 · NCT04502446 Terminated
Allogeneic CRISPR-Cas9 Engineered Anti-CD70… T Cell Lymphoma Phase 1 · NCT06492304 Completed
CTX310 Cardiovascular Phase 1 · NCT07491172 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRSP holds $2.3B in cash and short-term investments (as of Sep 30, 2026) and burns about $86.6M/quarter from operations, an estimated runway of 78.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRSP files for a raise →

👥 Who Owns CRSP

Insiders 2.6% Institutions (682 holders) 79.2% Public and other holders 18.2%
HolderTypeShares% of sharesAs of
ARK Investment Management LLC Institution (13G, 5%+) 10,056,844 10.37% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 7,987,262 8.23% 2026-06-30
STATE STREET CORPORATION Institution (13G, 5%+) 4,994,047 5.15% 2026-09-30
Capital World Investors Institution (13G, 5%+) 4,929,428 5.08% 2026-03-31
Simeon George
Director · +13,000 options
Insider 2,054,249 2.12% 2026-10-14
Samarth Kulkarni
Chief Executive Officer, Director · +200,499 options
Insider 311,899 0.32% 2026-10-16
James R. Kasinger
General Counsel and Secretary · +146,741 options
Insider 95,857 0.10% 2026-10-13
Naimish Patel
Chief Medical Officer · +74,499 options
Insider 19,357 0.02% 2026-05-28
Ali Behbahani
Director · +13,000 options
Insider 16,666 0.02% 2026-09-17
Raju Prasad
Chief Financial Officer · +107,159 options
Insider 14,815 0.02% 2026-08-07

Share count 97,000,813 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRSP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRSP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.